Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paroxetine as Adjunct Therapy in Rheumatoid Arthritis
NCT06231745Phase 3Completed
- Start
- Jan 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of paroxetine in rheumatoid arthritis (RA) (2 arms). Primary endpoint: 28-joints disease activity score at 3 months. Started Jan 2024; status: completed.
02
Drugs
paroxetine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06231745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231745.